Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill shows promise for bladder control in women

NCT ID NCT07312955

Symptom relief Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding tadalafil (a drug for erectile dysfunction and enlarged prostate) to solifenacin (a standard overactive bladder drug) works better than solifenacin alone for women with overactive bladder. 80 women aged 18 to 60 with symptoms for over 6 months took either both drugs or just solifenacin for 3 months. The goal was to see if the combination improved bladder symptoms like urgency and frequency more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

May 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 to 60 years. * Symptoms of overactive bladder for more than 6 months. * Not receiving current medical treatment for overactive bladder. * Normal liver function tests. * Normal kidney function. Exclusion Criteria: * Congestive heart failure or history of recent cardiovascular events. * Currently on medical treatment for overactive bladder. * Urinary tract infection (eligible only after treatment and resolution). * Urinary bladder stones. * Post-void residual urine \> 100 cubic centimeter (cm³). * Closed-angle glaucoma or recent ocular problems. * Postural hypotension. * History of neurological disorders (e.g., parkinsonism). * History of intestinal obstruction. * Pregnancy or planning pregnancy. * Myasthenia gravis. * Severe hepatic impairment. * History of hypersensitivity to solifenacin or tadalafil.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overactive bladder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Nocturia overactive bladder Urinary Incontinence, Urge

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overactive bladder

Contacts and locations

Locations

  • Ain Shams University Hospital (Urology Department)

    Cairo, Cairo Governorate, 11511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.